Literature DB >> 23716622

The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2+-dependent mechanism.

Emmanuel Kostakis1, Conor Smith, Ming-Kuei Jang, Stella C Martin, Kyle G Richards, Shelley J Russek, Terrell T Gibbs, David H Farb.   

Abstract

N-methyl D-aspartate (NMDA) receptors (NMDARs) mediate fast excitatory synaptic transmission and play a critical role in synaptic plasticity associated with learning and memory. NMDAR hypoactivity has been implicated in the pathophysiology of schizophrenia, and clinical studies have revealed reduced negative symptoms of schizophrenia with a dose of pregnenolone that elevates serum levels of the neuroactive steroid pregnenolone sulfate (PregS). This report describes a novel process of delayed-onset potentiation whereby PregS approximately doubles the cell's response to NMDA via a mechanism that is pharmacologically and kinetically distinct from rapid positive allosteric modulation by PregS. The number of functional cell-surface NMDARs in cortical neurons increases 60-100% within 10 minutes of exposure to PregS, as shown by surface biotinylation and affinity purification. Delayed-onset potentiation is reversible and selective for expressed receptors containing the NMDAR subunit subtype 2A (NR2A) or NR2B, but not the NR2C or NR2D, subunits. Moreover, substitution of NR2B J/K helices and M4 domain with the corresponding region of NR2D ablates rapid allosteric potentiation of the NMDA response by PregS but not delayed-onset potentiation. This demonstrates that the initial phase of rapid positive allosteric modulation is not a first step in NMDAR upregulation. Delayed-onset potentiation by PregS occurs via a noncanonical, pertussis toxin-sensitive, G protein-coupled, and Ca(2+)-dependent mechanism that is independent of NMDAR ion channel activation. Further investigation into the sequelae for PregS-stimulated trafficking of NMDARs to the neuronal cell surface may uncover a new target for the pharmacological treatment of disorders in which NMDAR hypofunction has been implicated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716622      PMCID: PMC3716320          DOI: 10.1124/mol.113.085696

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  65 in total

Review 1.  NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders.

Authors:  C Geoffrey Lau; R Suzanne Zukin
Journal:  Nat Rev Neurosci       Date:  2007-06       Impact factor: 34.870

Review 2.  Regulation of NMDA receptors by phosphorylation.

Authors:  Bo-Shiun Chen; Katherine W Roche
Journal:  Neuropharmacology       Date:  2007-06-02       Impact factor: 5.250

3.  Long-term potentiation selectively expressed by NMDA receptors at hippocampal mossy fiber synapses.

Authors:  Hyung-Bae Kwon; Pablo E Castillo
Journal:  Neuron       Date:  2008-01-10       Impact factor: 17.173

Review 4.  Metabotropic actions of kainate receptors in the CNS.

Authors:  Antonio Rodríguez-Moreno; Talvinder S Sihra
Journal:  J Neurochem       Date:  2007-09-20       Impact factor: 5.372

5.  D1 and D4 dopaminergic receptor interplay mediates coincident G protein-independent and dependent regulation of glutamate NMDA receptors in the lateral amygdala.

Authors:  Marzia Martina; Richard Bergeron
Journal:  J Neurochem       Date:  2008-07-24       Impact factor: 5.372

6.  Steroid pregnenolone sulfate enhances NMDA-receptor-independent long-term potentiation at hippocampal CA1 synapses: role for L-type calcium channels and sigma-receptors.

Authors:  Jilla Sabeti; Thomas E Nelson; Robert H Purdy; Donna L Gruol
Journal:  Hippocampus       Date:  2007       Impact factor: 3.899

Review 7.  Pregnenolone sulfate in the brain: a controversial neurosteroid.

Authors:  Michael Schumacher; Philippe Liere; Yvette Akwa; Krzysztof Rajkowski; William Griffiths; Karl Bodin; Jan Sjövall; Etienne-Emile Baulieu
Journal:  Neurochem Int       Date:  2007-10-09       Impact factor: 3.921

8.  PREGS induces LTP in the hippocampal dentate gyrus of adult rats via the tyrosine phosphorylation of NR2B coupled to ERK/CREB [corrected] signaling.

Authors:  Ling Chen; Yoshiaki Miyamoto; Kishio Furuya; Nozomu Mori; Masahiro Sokabe
Journal:  J Neurophysiol       Date:  2007-07-11       Impact factor: 2.714

9.  Pregnenolone sulfate induces NMDA receptor dependent release of dopamine from synaptic terminals in the striatum.

Authors:  Matthew T Whittaker; Terrell T Gibbs; David H Farb
Journal:  J Neurochem       Date:  2008-08-14       Impact factor: 5.372

10.  Pharmacological Properties of DOV 315,090, an ocinaplon metabolite.

Authors:  Dmytro Berezhnoy; Maria C Gravielle; Scott Downing; Emmanuel Kostakis; Anthony S Basile; Phil Skolnick; Terrell T Gibbs; David H Farb
Journal:  BMC Pharmacol       Date:  2008-06-13
View more
  20 in total

1.  The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.

Authors:  Steven M Paul; James J Doherty; Albert J Robichaud; Gabriel M Belfort; Brian Y Chow; Rebecca S Hammond; Devon C Crawford; Andrew J Linsenbardt; Hong-Jin Shu; Yukitoshi Izumi; Steven J Mennerick; Charles F Zorumski
Journal:  J Neurosci       Date:  2013-10-30       Impact factor: 6.167

2.  Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder.

Authors:  Lawrence K Fung; Robin A Libove; Jennifer Phillips; Francois Haddad; Antonio Y Hardan
Journal:  J Autism Dev Disord       Date:  2014-11

3.  Adrenocorticotropin Acutely Regulates Pregnenolone Sulfate Production by the Human Adrenal In Vivo and In Vitro.

Authors:  Juilee Rege; Aya T Nanba; Richard J Auchus; Jianwei Ren; Hwei-Ming Peng; William E Rainey; Adina F Turcu
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

4.  Sex Differences Distinguish Intracortical Glutamate Receptor-Mediated Regulation of Extracellular Dopamine Levels in the Prefrontal Cortex of Adult Rats.

Authors:  M N Locklear; A B Cohen; A Jone; M F Kritzer
Journal:  Cereb Cortex       Date:  2014-09-26       Impact factor: 5.357

Review 5.  Divergent neuroactive steroid responses to stress and ethanol in rat and mouse strains: relevance for human studies.

Authors:  Patrizia Porcu; A Leslie Morrow
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

Review 6.  Pregnenolone sulfate as a modulator of synaptic plasticity.

Authors:  Conor C Smith; Terrell T Gibbs; David H Farb
Journal:  Psychopharmacology (Berl)       Date:  2014-07-06       Impact factor: 4.530

7.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

8.  A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation.

Authors:  Conor C Smith; Stella C Martin; Kavitha Sugunan; Shelley J Russek; Terrell T Gibbs; David H Farb
Journal:  Mol Pharmacol       Date:  2014-07-23       Impact factor: 4.436

9.  Visualizing pregnenolone sulfate-like modulators of NMDA receptor function reveals intracellular and plasma-membrane localization.

Authors:  Mariangela Chisari; Timothy J Wilding; Samuel Brunwasser; Kathiresan Krishnan; Mingxing Qian; Ann Benz; James E Huettner; Charles F Zorumski; Douglas F Covey; Steven Mennerick
Journal:  Neuropharmacology       Date:  2018-10-15       Impact factor: 5.250

Review 10.  Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.

Authors:  Erica S Burnell; Mark Irvine; Guangyu Fang; Kiran Sapkota; David E Jane; Daniel T Monaghan
Journal:  J Med Chem       Date:  2018-03-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.